Kornimate/medical-research-clean huggingface dataset:
effectiveness of cbt in improving psycho-neuro-endocrine factors in women following in vitro fertilization program

Conditions: Cognitive Behavioral Therapy; Hormone Disturbance; In Vitro Fertilization

Summary: the goal of this clinical trial is to learn if cognitive behavioral therapy (cbt) can improve psychological, neurological, and hormonal aspects in women undergoing in vitro fertilization (ivf). the main questions it aims to answer are: * is cbt effective in improving psychological aspects (anxiety, depression, and coping mechanism) in women undergoing ivf? * is cbt effective in improving neuroendocrine aspects (cortisol levels, neuroepinephrine levels, free trioodothyronine levels) in women underoing ivf? researchers will compare cbt to no intervention to see if cbt is effective in improving psychoneuroendocrine aspects.

participants will * attend 8 appointments once a week, during which they will be given cbt or no intervention * have their anxiety score, depression score, and dominant coping mechanism assessed before the first appointment and during appointment 3, 6, and 8 * have their cortisol levels, norepinephrine levels, and free triiodothyronine levels assessed before the first appointment and during appointment 3, 6, and 8

Eligibility criteria:
inclusion criteria: * women with primary infertility * aged 25-42 at the start of the study * willing to participate in the study and willing to sign informed consent form * minimum education of high school, able to read, write and understand bahasa indonesia exclusion criteria: * having one or multiple psychotic disorder(s)

Keywords: cognitive behavioral therapy psycho-neuro-endocrine in vitro fertilization
low intensity shockwave therapy for ed in non responders to pde5i - a double blind placebo controlled study

Conditions: Erectile Dysfunction

Summary: low intensity shock waves (lisw) have been proven in animal studies to induce local growth of new blood vessels. the investigators hypothesized that lisw therapy could improve the symptoms of patients with erectile dysfunction resulting from a problem of blood supply that do not respond to oral therapy (pde-5 inhibitors).

in this study low intensity shockwaves (1/10 the ones used in lithotripsy) are delivered directly to the penile tissue using a specially designed shockwave device and probe. shock wave therapy is applied twice a week for three weeks , then a 3- week interval with no therapy followed by another 3 week period of twice a week shock wave therapy. before and after sexual function questionnaires and objective measures of erectile function will be performed.

Eligibility criteria:
inclusion criteria: * ed of more than 6 months * rigidity score \< 3 during pde5i therapy * shim \<21 during pde5i therapy * non- hormonal, neurological or psychological pathology stable heterosexual relationship for more than 3 months exclusion criteria: * prior prostatectomy surgery * any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities * clinically significant chronic hematological disease * anti-androgens, oral or injectable androgens * radiotherapy in pelvic region

Keywords: erectile dysfunction pde5 inhibitor low intensity shock wave therapy.
mendip: measurements of overnight penile temperature to evaluate nocturnal erection detection in patients with absence of erectile functioning after robot-assisted radical prostatectomy

Conditions: Erectile Dysfunction; Erectile Dysfunction Following Radical Prostatectomy

Summary: nocturnal erection detection with the outdated rigiscan is the golden standard for erectile dysfunction (ed) nature differentiation. the staying hot and feeling hot study have shown that nocturnal erection detection is feasible with patient-friendly overnight penile temperature measurements. the question has arisen whether the penile temperature methodology is also capable to detect the absence of nocturnal erections, which is essential for clinical implementation in erectile dysfunction diagnostics. the objective of the mendip-study is to determine the feasibility to detect the absence of nocturnal erections with overnight penile temperature sensors. furthermore, the mendip study functions as a first pilot trial to investigate the effect of age on the penile temperature during nocturnal erections in test subjects with normal erectile functioning. this is done in an observational study with a longitudinal design in which pre- and postoperative ambulatory overnight measurements are performed in patients, aged 55 - 70 years with preoperative normal sexual functioning, undergoing a non- or unilateral nerve-sparing robot assisted radical prostatectomy.


Eligibility criteria:
inclusion criteria: 1. preoperative measurement: * aged 55 - 70 years * prostatecancer patients undergoing a non-/unilateral-nerve-sparing radical prostatectomy (rarp) * pre-operative iief-5 score \> 21 2. postoperative measurement * inclusion criteria of pre-operative measurement * preoperative penile temperature increase during first nocturnal erection of minimally 0.4 degrees celsius * post-operative iief-5 score \< 12 with absence of morning erections exclusion criteria: * test subjects who are unwilling to sign informed consent * test subjects with erectile dysfunction before rarp (iief-5 score of below 22) * (history of) sickle cell aneamia, atherosclerosis and diabetes type i or ii. these conditions might influence penile blood circulation and therefore the accuracy of the study outcomes. * (history of) rem-sleep behavior disorder or other sleep disorders such as restless legs syndrome, insomnia, and sleep apnea * usage of sleeping pills or benzodiazepines. * postoperative results will be excluded from the study in case of presence of nocturnal erections according to the rigiscan data.

Keywords: erectile dysfunction nocturnal erection rigiscan penile temperature
volume-controlled ventilation and pressure-controlled ventilation volume guaranteed in obese patients in laparoscopic-assisted surgery

Conditions: Volume-Controlled Ventilation; Pressure-Controlled Ventilation Volume Guaranteed; Obese; Laparoscopy

Summary: the aim of this study is to compare the efficacy of the pressure controlled ventilation volume-guaranteed (pcv-vg) versus volume-controlled ventilation (vcv) modes as regards lung compliance and oxygenation index in obese patients undergoing laparoscopic assisted surgery especially in trendelenburg position.

obesity, defined as a body mass index (bmi) \>30 kg.m-2", is characterized by increased airway resistance, labored breathing and decreased respiratory system compliance. an increased rate of obese patients undergoing laparoscopic assisted surgery (las) is a health care concern due to anesthesia and ventilation difficulties in the obese population. therefore, understanding the physiology and pathophysiology of lung function is an important issue during long-lasting las. carbon dioxide pneumoperitoneum with steep trendelenburg positioning leads to a cranial displacement of the diaphragm and an increased volume of atelectasis, with a consequent decrease of total lung volume, lung compliance, and functional residual capacity. thus, alleviation of increased airway pressure, improvement in oxygenation and co2 elimination are the main goals during anesthetic management in laparoscopic assisted surgery. in pressure controlled ventilation volume-guaranteed (pcv-vg) mode, the ventilator regulates the peak inspiratory pressure (pip) to achieve the optimal tv. to achieve the target volume, ventilator parameters are regularly changed without adjusting airway pressures. hence, pcv-vg has the advantages of both volume-controlled ventilation (vcv) and pressure controlled ventilation (pcv) to preserve the target minute ventilation while maintaining a low incidence of barotraumas. pcv-vg is a type-controlled ventilation mode with a dual character as it has the criteria of both pcv and vcv. this recent ventilation mode which is one of the pressure regulated volume controlled (prvc) that include auto flow ventilation, offers the ability to reduce the inspiratory pressure and as a result the incidence of barotrauma

Eligibility criteria:
inclusion criteria: 1. age: 16 - 60 years old. 2. sex: both males and females. 3. undergoing elective laparoscopic surgery. 4. obese patient with body mass index between ≥30 kg/m2. 5. american society of anesthesiologist (asa) class i/ ii. exclusion criteria: 1. patient refusal. 2. american society of anesthesiology (asa) iii or iv. 3. intraoperative hemodynamic instability. 4. patients with pulmonary hypertension. 5. obese patients on home o2 therapy 6. pneumoperitoneum with co2 with intra-abdominal pressure exceeding 15mmhg. 7. anti-trendelenburg position. 8. asthmatic patients. 9. patients with advanced liver disease. 10. patients with advanced renal disease. 11. patients with advanced malignancy. 12. pregnant females.
metabolomics characterization of biomarkers of different types of myocardial infarction in different time.

Conditions: Myocardial Infarction

Summary: to find new biomarkers through metabonomics study of different types of myocardial infarction in different time.

in recent years, with the deepening understanding of the mechanism of myocardial infarction, in addition to the early understanding of plaque rupture, plaque erosion and other mechanisms, studies have found that inflammation, immunity, metabolism and other factors also play an increasingly important role in the occurrence and development of myocardial infarction. the lodoco2 study published at the 2020 esc annual meeting and the colcot study previously published confirmed for the first time the therapeutic effect of anti-inflammatory drug colchicine in chronic coronary disease and acute myocardial infarction. at the same time, the fourth international definition of myocardial infarction also defines three different types of acute st segment elevation myocardial infarction (stemi), acute non st segment elevation myocardial infarction (nstemi) and non infarct acute myocardial infarction (minoca). however, there are no clear research results on the mechanism, especially the mechanism of minoca. therefore, the study of acute myocardial infarction in three groups is of great significance.

Eligibility criteria:
inclusion criteria: 1.the patient clearly had acute myocardial infarction. 2.the patient's serum cardiac markers (mainly troponin) were elevated (at least above the upper limit of 99% reference value) and accompanied by one of the following clinical indicators： 1. ischemic symptoms 2. new ischemic ecg changes, new st-t changes or left bundle branch block（lbbb）. 3. pathological q wave formation in ecg 4. imaging evidence showed new loss of myocardial activity or new regional wall motion abnormalities. 5. the thrombus was confirmed by coronary angiography. 3．the patient had chest pain symptoms, but coronary angiography showed normal coronary artery (such as intercostal neuralgia, cervical spondylosis, chest pain of unknown origin, etc.) exclusion criteria: 1. refusal to sign informed consent. 2. surgical treatment was performed in the last three months. 3. patients with a history of the following diseases or consider the diagnosis of the following diseases：stress cardiomyopathy, myocarditis, pericarditis, pneumonia, pulmonary embolism, aortic dissection. 4. severe heart failure, grade iv cardiac function. 5. liver and kidney dysfunction. 6. blood-borne diseases, including hiv / aids, hepatitis b, hepatitis c, etc. 7. patients with a history of malignancies, autoimmune diseases, severe infectious diseases and trauma. 8. previous history of myocardial infarction and stroke.

Keywords: myocardial infarction metabolomics biomarkers
suspension therapy effects on mobility and balance in down syndrome

Conditions: Down Syndrome (DS)

Summary: down syndrome (ds) is one of the most common congenital disorders. individuals with down syndrome present with several impairments such as hypotonia, ligament laxity, decreased muscle strength, insufficient muscular co-contraction, inadequate postural control, and disturbed proprioception. these factors are responsible for the developmental challenges faced by children with down syndrome. these individuals also present with balance dysfunctions. neuromuscular and musculoskeletal impairments due to the chromosomal abnormality lead to developmental delay. these children also exhibit poor balance with greater instability and inefficient compensatory mechanisms including altered center of pressure displacement and trunk stiffening that predisposes them to falls. the aim of this study is to determine the effects of suspension therapy (st) on mobility and balance of children with down syndrome. suspension therapy using universal exercise unit (ueu) is a three dimensional (3d) cage, consists of system of pulleys, suspensions, belts for supporting and elastic cords. suspension therapy is based on the concept of unloading the body against gravity and to perform movement of weak part of body.

the current study will be randomized controlled trial. inclusion criteria for the study will be children with down syndrome (ds) of mild to moderate mental retardation aged between 3 and 6 years. patients with any cardiac issue and orthopedic limitation to exercise such as hip, knee, foot or spinal deformities will be excluded from the study. a sample of 26 children with ds will be selected from both genders. tools used for data collection will be pediatric balance scale (pbs), four square step test (fsst), timed up and go test (tug) and 1minute walk test (1mwt). participants will be measured before and after treatment to assess changes. interventions are carried out 5 days in a week for one hour daily. in this study descriptive statistical tools will used to analyze the data. data will be analyzed through spss version 23.00.

Eligibility criteria:
inclusion criteria: • diagnosed children with down syndrome with mild (iq: 69-50) to moderate (iq: 50-35) mental retardation * aged between 3 to 6 years * both gender * able to follow the instructions * able to stand and walk exclusion criteria: • any cardiovascular disease * visual and hearing impairment * orthopedic limitation to exercise such as hip, knee, foot or spinal deformities

Keywords: down syndrome suspension therapy universal exercise unit pediatric balance scale four square step test 1min walk test timed up and go test
powdered fermented fruits for glycemia reduction

Conditions: Cardiometabolic Risk Factors; Obesity, Abdominal

Summary: the aim of the study is to evaluate the effects of an acute intake of two fermented fruits flours as part of a standardized breakfast, in comparison with the acute intake of a standardized breakfast without fermented fruits flour but with the same amount of available carbohydrates, on postprandial glycaemic response and overall metabolism in subjects at cardiometabolic risk. the metabolic parameters will be assessed in fasting and in postprandial period after the consumption of the standardized breakfast.


Eligibility criteria:
inclusion criteria: * body mass index between 25 and 35 kg/m2 inclusive * waist circumference \> 80 cm for women and \> 96 cm for men * fibers intake ≤ 25g/day exclusion criteria: * history of digestive surgery or diseases * current or recent (\<12 weeks) intake of antibiotics or gastro-intestinal medicinal product * current probiotics, prebiotics, fibers complement, and/or any products modulating glucose and lipid metabolism * volunteer with a dietary restriction (vegetarian or high-protein diet for example) * current weight loss diet * pregnant or lactating woman or woman who do not use effective contraception * drinking more than 3 glasses of alcohol per day (\>30g/day) * smoking volunteer

Keywords: postprandial glycaemia dietary fibers cardiometabolic risk fermented fruit flour
assessing the japet.w+ lumbar traction device in rehabilitation for patients with non-specific mechanical low back pain

Conditions: Low Back Pain, Mechanical

Summary: the study will include patients suffering from nonspecific mechanical low back pain for more than 6 weeks. two groups will be compared. a control group and an experimental group with the exoskeleton japet.w

the study will include patients suffering from nonspecific mechanical low back pain for more than 6 weeks. the study will consist of two groups: a control group (group ctrl) and an experimental group (group exp). participants will be categorized into two categories: "workers," patients on temporary work leave due to low back pain, and "non-workers," patients unable to work due to this condition after exhausting all available therapeutic solutions. monitoring period (30 physiotherapy sessions): evaluations will be conducted at sessions 1, 15 and 30, on the two groups. evaluation session 3 months after the end of the physiotherapy sessions.

Eligibility criteria:
inclusion criteria: * nonspecific mechanical low back pain for more than 6 weeks, * 18 years ≤ age \< 80 years, * patient affiliated to the health social security system, * patient able to understand the information relating to the study and to sign the informed consent form exclusion criteria: * specific low back pain (infectious, inflammatory, tumorous, or traumatic origin), * motor neurological deficits (peripheral or central), * extrapyramidal syndrome, * treatment with implanted neurostimulation, * cardiac or circulatory diseases or serious respiratory problems, * previous recent arthrodesis or recent lumbar prosthesis surgery, * surgery for herniated disc (\<3 months), * fracture of the dorsolumbar spine or rib (\<3 months), * skin lesions, contusions and stretching injuries of the trunk, * pregnancy, * individuals not tolerating the japet.w+ device during an initial trial, * under guardianship, curatorship or legal protection
refractoriness to ibrutinib btki and systemic targeted therapy

Conditions: CLL, Relapsed; CLL, Refractory; Bruton Tyrosine Kinase Inhibitor; Small Lymphocytic Leukemia

Summary: data evaluating and quantifying real-world outcomes of patients post-ibrutinib discontinuation, as well as outcomes of patients who have progressed on a bruton tyrosine kinases inhibitors (btki) and received prior venetoclax are very limited. there are no robust studies specifically designed to assess outcomes of patients with chronic lymphocytic leukemia (cll) receiving third line or subsequent treatments. as such, there is no established standard of care for these multiple relapsed/refractory (rr) patients. furthermore, despite new oral agents approved in third-line rr cll, there are limited published data on how to best sequence these agents and how to manage patients who fail these therapies. as the best salvage therapy in patients who fail all available oral these agents is unknown, this is a population of patients with unmet medical need. the aim of this study is to determine unmet need and treatment patterns of data from two types of populations, all previously exposed to ibrutinib (or other btki) for the full patient population and both ibrutinib (or other btki and venetoclax) for the narrow patient population, where these agents failed these subcategories of patient populations, at least in 3rd line therapy (in other words, having at least received two lines of therapy before) * patients with prior treatment with btki (full patient population) - underlying tenet: these patients have been treated with a btki in at least one of two or more prior lines of therapy and progressed - full population * patients who progressed btki and failed ven (defined as patients who discontinued venetoclax (ven) due to disease progression, intolerability, or failure to achieve an objective response within 3 months of initiating therapy; small patient population) - tenet: these patients have been treated with both btki and ven in any one of the prior two lines of therapy and progressed. - narrow population


Eligibility criteria:
inclusion criteria: * documented diagnosis of cll or small lymphocytic leukemia (sll). * ≥ 18 years of age the time of initial diagnosis. * venetoclax therapy in at least third line of treatment (lot) during the period considered, following at least one lot with btki * patients who received ven during prior lots are eligible. * patient not opposed to data collection (including deceased patients) exclusion criteria: * exposure to cellular therapy, including car t-cells / allo-stem cell transplantation. * richter's transformation.
improving gait in persons with knee related mobility limitations by rosenoids® food supplement: a randomized double-blind placebo-controlled trial

Conditions: Knee Related Walking Limitations

Summary: knee related mobility limitations are the leading cause of disability in the western world. it is a very expensive and debilitating condition when the cost of lost productivity and personal assistance is considered. in recent years there has been a growing interest in alternative medicine and many individuals seek such treatments. rosehip, that is sold as a nutritional supplement, has been particular popular, and has been shown effective in relieiving pain - albeit the evidence is scarce. the purpose of this study is to evaluate the efficacy of specialized rosehip powder nutritional additives (rosenoids®) on knee joint function during walking in subjects with knee-related walking limitations.


Eligibility criteria:
inclusion criteria: * aged above 40 * self-reported knee-related walking disability * in general good health, in the opinion of the investigator, based on medical history and physical examination and, if necessary, laboratory values. laboratory tests are prescribed by the investigator at the screening visit. * a body mass index (bmi) of ≤35 kg/m2 * speaks, reads and writes danish language exclusion criteria: * usage of rosehip nutritional supplements within the last 3 months * history of symptoms of autoimmune disorders. * planned surgical procedure during the duration of the study * history, diagnosis, or signs and symptoms of clinically significant neurological disease * alcohol or drug abuse within the last 5 years * history, diagnosis, signs or symptoms of any clinically significant psychiatric disorder * subjects with regional pain syndromes suggestive of lumbar compressions with radiculopathy or at risk of developing radiculopathy. * any other condition, which in the opinion of the investigator, would put the subject at increased safety risk or otherwise make the subject unsuitable for this study.